Involvement of cytochrome P-450 isozymes in melatonin metabolism and clinical implications.
Yeleswaram
K
K
Vachharajani
N
N
Santone
K
K
D002460:Cell Line; D018849:Controlled Clinical Trials as Topic; D019363:Cytochrome P-450 CYP1A1 / Q000378:metabolism; D019388:Cytochrome P-450 CYP1A2 / Q000378:metabolism; D065609:Cytochrome P-450 CYP1A2 Inhibitors; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D019587:Dietary Supplements / Q000009:adverse effects; D004347:Drug Interactions; D006801:Humans; D020128:Inhibitory Concentration 50; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008550:Melatonin / Q000009:adverse effects / Q000378:metabolism* / Q000494:pharmacology
D065609:Cytochrome P-450 CYP1A2 Inhibitors; D065607:Cytochrome P-450 Enzyme Inhibitors; D007527:Isoenzymes; D003577:Cytochrome P-450 Enzyme System; D019363:Cytochrome P-450 CYP1A1; D019388:Cytochrome P-450 CYP1A2; D008550:Melatonin